Pharma lobby pledges to launch drugs on EU markets no later than two years after approval
European regional differences are too large in regard to the time it takes for drugs to reach individual EU countries post approval, says European lobby organization EFPIA, which is launching a new initiative to reduce inequalities in the area.
by andreas lønstrup, translated by daniel pedersen
On Monday, the European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents pharmaceutical firms across Europe, has made a pledge to ”reduce inequalities in patient access to medicines across Europe,” the organization has announced in a press release, as reported by Endpoints News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish Medicines Council considers fast-track scheme
For subscribers
